AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: GSK2118436

First Posted Date: 2012-04-23

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT01582997

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

Phase 3

Completed

Conditions: Acellular Pertussis
Tetanus
Haemophilus Influenzae Type b
Poliomyelitis
Diphtheria
Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Interventions: Biological: Infanrix-IPV+Hib™

First Posted Date: 2012-04-16

Last Posted Date: 2020-01-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 321

Registration Number: NCT01577732

Locations: 🇻🇳
GSK Investigational Site, Hai Phong, Vietnam

Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects

Phase 1

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: dutasteride

First Posted Date: 2012-04-16

Last Posted Date: 2018-06-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 35

Registration Number: NCT01577693

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Inhaled GSK573719/vilanterol
Drug: Inhaled GSK573719

First Posted Date: 2012-04-16

Last Posted Date: 2017-07-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT01577680

Locations: 🇸🇰
GSK Investigational Site, Bratislava, Slovakia

A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278

Phase 1

Completed

Conditions: Huntington Disease

Interventions: Drug: GSK356278
Drug: Placebo

First Posted Date: 2012-04-10

Last Posted Date: 2017-06-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT01573819

Locations: 🇳🇱
GSK Investigational Site, Zuidlaren, Netherlands

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone propionate 100mcg
Drug: Vilanterol
Drug: Placebo

First Posted Date: 2012-04-10

Last Posted Date: 2017-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 463

Registration Number: NCT01573767

Locations: 🇺🇦
GSK Investigational Site, Zaporizhia, Ukraine

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: FF/GSK573719
Drug: FF/VI
Drug: FF

First Posted Date: 2012-04-09

Last Posted Date: 2017-10-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 421

Registration Number: NCT01573624

Locations: 🇹🇭
GSK Investigational Site, Nonthaburi, Thailand

A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Biological: Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)